- ►nursing2008.com RS Hundal, SE Inzucchi - Drugs, 2003 - ingentaconnect.com Metformin, a biguanide, has been available in the US for the treatment of type Abstract 2 diabetes
mellitus for nearly 8 years. Over this period of time, it has become the most widely prescribed
antihyperglycaemic agent. Its ... Cited by 113 - Related articles - BL Direct - All 7 versions
MA Nauck, JJ Meier - Regulatory peptides, 2005 - Elsevier Glucagon-like peptide 1 (GLP-1) was discovered as an insulinotropic gut hormone, suggesting a
physiological role as an incretin hormone, ie, being responsible, in part, for the higher insulin
secretory response after oral as ... Cited by 107 - Related articles - All 6 versions
- ►diabetesjournals.org BJ Goldstein, MN Feinglos, JK Lunceford, J … - Diabetes Care, 2007 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—In a 24-week, randomized, double-blind, placebo-controlled,
parallel-group study, 1,091 patients with type 2 diabetes and A1C 7.5–11% were randomized to one
of six daily treatments: ... Cited by 96 - Related articles - BL Direct - All 9 versions
JR Lindsay, NA Duffy, AM McKillop, J Ardill, … - Diabetic …, 2005 - interscience.wiley.com Aims Glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP) are important
insulinotropic hormones that enhance the insulin secretory response to feeding. Their potential for
treating Type 2 diabetes is limited ... Cited by 44 - Related articles - All 5 versions
N Yasuda, T Inoue, T Nagakura, K Yamazaki, K … - … and Biophysical Research …, 2002 - Elsevier Metformin was reported to increase plasma active glucagon-like peptide-1 (GLP-1) in humans. There
are two possible mechanisms for this effect: (1) metformin inhibits dipeptidyl peptidase IV (DPPIV),
an enzyme degrading GLP-1, and (2) ... Cited by 43 - Related articles - BL Direct - All 6 versions
- ►cyclicamp.ca [PDF] SA Hinke, K Kühn-Wache, T Hoffmann, RA … - … and Biophysical Research …, 2002 - Elsevier There is current interest in the use of inhibitors of dipeptidyl peptidase IV (DP IV) as therapeutic
agents to normalize glycemic excursions in type 2 diabetic patients. Data indicating that metformin
increases the circulating amount of ... Cited by 42 - Related articles - BL Direct - All 5 versions
- ►dvdres.com [PDF] BD Green, PR Flatt, CJ Bailey - Diabetes & Vascular Disease …, 2006 - dvr.sagepub.com Abstract I nhibitors of the enzyme dipeptidyl peptidase IV (DPP IV) provide a strategy for the
treatment of type 2 dia- betes. DPP IV rapidly inactivates the incretin hor- mones glucagon-like
peptide-1 (GLP-1) and glucose- ... Cited by 40 - Related articles - BL Direct - All 9 versions
CF Deacon, JJ Holst - Biochemical and Biophysical Research …, 2002 - Elsevier We have read with interest the recent paper by Hinke et al. [1], which appeared in the March issue
of Biochemical and Biophysical Research Communications. In their paper, Hinke et al. describe the
potential of inhibitors of ... Cited by 38 - Related articles - BL Direct - All 5 versions
- ►diabetesjournals.org T Damci, S Yalin, H Balci, Z Osar, U Korugan, M … - Diabetes Care, 2004 - Am Diabetes Assoc OBJECTIVE—Orlistat leads to improved glycemic control in obese type 2 diabetic patients, which is
attributed to decreased insulin resistance associated with weight loss. Glucagon-like peptide 1
(GLP-1) and glucose-dependent ... Cited by 37 - Related articles - BL Direct - All 11 versions
E Mannucci, L Pala, S Ciani, G Bardini, A Pezzatini, I … - Diabetologia, 2005 - Springer Abstract Aims/hypotheses: Chronic hyperglycaemia in-
creasesdipeptidylpeptidaseIV(DPP-IV)activityinendothe- lial cells in vitro. The present study was
designed to assess the effect of ... Cited by 37 - Related articles - All 4 versions
